<!DOCTYPE html>
<!--
==============================================================================
           "GitHub HTML5 Pandoc Template" v2.1 — by Tristano Ajmone           
==============================================================================
Copyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:

- https://github.com/tajmone/pandoc-goodies

The CSS in this template reuses source code taken from the following projects:

- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):
  https://github.com/sindresorhus/github-markdown-css

- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):
  http://primercss.io/

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
The MIT License 

Copyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)
Copyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)
Copyright (c) 2017 GitHub Inc.

"GitHub Pandoc HTML5 Template" is Copyright (c) Tristano Ajmone, 2017, released
under the MIT License (MIT); it contains readaptations of substantial portions
of the following third party softwares:

(1) "GitHub Markdown CSS", Copyright (c) Sindre Sorhus, MIT License (MIT).
(2) "Primer CSS", Copyright (c) 2016 GitHub Inc., MIT License (MIT).

Permission is hereby granted, free of charge, to any person obtaining a copy
of this software and associated documentation files (the "Software"), to deal
in the Software without restriction, including without limitation the rights
to use, copy, modify, merge, publish, distribute, sublicense, and/or sell
copies of the Software, and to permit persons to whom the Software is
furnished to do so, subject to the following conditions:

The above copyright notice and this permission notice shall be included in all
copies or substantial portions of the Software.

THE SOFTWARE IS PROVIDED "AS IS", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR
IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE
AUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER
LIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,
OUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE
SOFTWARE.
==============================================================================-->
<html>
<head>
  <meta charset="utf-8" />
  <meta name="generator" content="pandoc" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes" />
  <title>Hyponatraemia and hypernatraemia MeG-CLS-072</title>
  <style type="text/css">
@charset "UTF-8";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,"Segoe UI",Helvetica,Arial,sans-serif,"Apple Color Emoji","Segoe UI Emoji","Segoe UI Symbol";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:""}.markdown-body hr::after{display:table;clear:both;content:""}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:" "}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:""}.markdown-body::after{display:table;clear:both;content:""}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}
  </style>
  <style type="text/css">code{white-space: pre;}</style>
  <!--[if lt IE 9]>
    <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js"></script>
  <![endif]-->
</head>
<body>
<article class="markdown-body">
<h1 id="hyponatraemia-and-hypernatraemia">Hyponatraemia and hypernatraemia</h1>
<h2 id="executive-summary"><em>Executive summary</em></h2>
<h2 id="introduction">Introduction</h2>
<p>Abnormalities in serum sodium are relatively common in our admitted population – especially in those with hypertension, heart failure or liver disease. An abnormal sodium level has been shown to be associated with poor outcome following hospital admission. It is very important that these abnormalities are noticed and responded to as soon as possible.</p>
<p>Remember that abnormalities can result from laboratory errors or other factors around specimen collection and storage. It is very important to relate any abnormal results to the clinical state of the patient and to repeat the laboratory test whenever there is any uncertainty.</p>
<p>Note:</p>
<p>TBW (men) = 0.6 L/kg × weight in kg</p>
<p>TBW (women) = 0.5 L/kg × weight in kg</p>
<h2 id="target-users">Target users</h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Doctors</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Nurses</p>
</div></li>
</ul>
<h2 id="target-area-of-use">Target area of use </h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Outpatient department</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Ward</p>
</div></li>
</ul>
<h2 id="key-areas-of-focus-new-additions-changes">Key areas of focus / New additions / Changes </h2>
<p>This guideline describes the correction of abnormal sodium results.</p>
<p>Note that great care should be taken in correcting the sodium level in malnourished children. Commonly, these children have raised total body sodium even if the serum sodium level is reduced. Usually the blood results will improve as the nutrition status improves.</p>
<p>Rapid shifts in serum sodium are associated with irreversible brain injury so correction must be undertaken cautiously.</p>
<h2 id="limitations">Limitations</h2>
<p>We do not keep hypertonic or hypotonic sodium solutions.</p>
<h1 id="hyponatraemia">Hyponatraemia</h1>
<p>This is defined as Na &lt; 135 mmol/L. It is severe if ≤ 120 mmol/L.</p>
<h2 id="causes">Causes</h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Isotonic hyponatraemia: hyperlipidemia or proteinaemia</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Hypertonic hyponatraemia: glucose or mannitol infusion.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Euvolemic hyponatraemia: syndrome of inappropriate ADH (SIADH) secretion, hypothyroidism, adrenal insufficiency and medications such as thiazide diuretics, NSAIDs and SSRIs</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Hypovolemic: haemorrhage, vomiting, diarrhoea, burns</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Hypervolemic: congestive heart failure, liver cirrhosis.</p>
</div></li>
</ul>
<h2 id="presenting-symptoms-and-signs">Presenting symptoms and signs</h2>
<p>Symptoms and signs are usually obvious in patients who have sudden onset of hyponatraemia or have severe hyponatraemia and they include :</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Headache</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Lethargy</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Nausea</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Depressed reflexes</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Disorientation</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Seizures</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Coma</p>
</div></li>
</ul>
<p>Other symptoms and signs are dependent on the volume status of the patient:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Dizziness, postural hypotension and syncope – hypovolaemia</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Peripheral oedema, pleural effusion or ascites – hypervolaemia</p>
</div></li>
</ul>
<h2 id="management">Management</h2>
<p>Medications such as diuretics should be reviewed or stopped if they are thought to be responsible for hyponatraemia.</p>
<p>The causes of hyperlipidaemia and hyperproteinaemia should be found and treated.</p>
<p>Endocrinologic disorders should be managed accordingly. SIADH is managed with fluid restriction at first and then diuresis if there is no improvement.</p>
<p>The treatment of hypervolemic hyponatraemia is with diuresis - preferably loop diuretics.</p>
<h3 id="correction">Correction</h3>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Na deficit (mmol/L) = Total Body Water (TBW) × (140 – measured serum Na concentration)</p>
</div></li>
</ul>
<p>Normal saline is used for correction of hyponatremia in our setting and this can be calculated using the following formula:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Change in serum Na = Infusate Na – Serum Na / (total body water +1)</p>
</div></li>
</ul>
<p>This gives the change in serum sodium per litre of infusate. Note: Infusate Na is 154 mmol/L for 0.9% saline intravenous infusion.</p>
<div data-custom-style="List Paragraph">
<p>Use the calculator on this website to determine the infusion rate: <a href="https://www.mdcalc.com/sodium-correction-rate-hyponatremia-hypernatremia"><span data-custom-style="Hyperlink">https://www.mdcalc.com/sodium-correction-rate-hyponatremia-hypernatremia</span></a></p>
</div>
<p>Correction should be done at a rate of 1-2 mmol/L/hour (in acute conditions) or 0.5 mmol/L/hour (in chronic conditions) over 40 hours. Fifty percent of the fluid should be given in the 1st 24 hrs and not exceeding 12 mmol/24hrs. This is to prevent cerebral pontine myelinolysis</p>
<p>Monitoring of serum Na should be done after every 4-6 hours.</p>
<h1 id="hypernatraemia">Hypernatraemia</h1>
<p>This is defined as Na &gt; 145 mmol/L. It is severe if ≥ 160 mmol/L.</p>
<h2 id="causes-1">Causes </h2>
<table>
<thead>
<tr class="header">
<th><strong>Type of fluid loss or gain</strong></th>
<th><strong>Causes</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Net water loss</td>
<td><ul>
<li><div data-custom-style="List Paragraph">
<p>Unreplaced insensible loss (dermal and respiratory)</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Inadequate fluid intake/impaired thirst – typically in elderly people</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Diabetes insipidus</p>
</div></li>
</ul></td>
</tr>
<tr class="even">
<td>Hypotonic fluid loss</td>
<td><ul>
<li><div data-custom-style="List Paragraph">
<p>Renal causes, e.g. osmotic diuresis in uncontrolled diabetes</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Medicines, e.g. loop diuretics, mannitol, urea, corticosteroids (increase production of urea), high protein supplements</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Gastrointestinal losses, e.g. diarrhoea, vomiting, fistulae, use of osmotic laxatives (lactulose, sorbitol)</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Cutaneous loss, e.g. burns, excessive sweating</p>
</div></li>
</ul></td>
</tr>
<tr class="odd">
<td>Hypertonic fluid gain</td>
<td><ul>
<li><div data-custom-style="List Paragraph">
<p>Ingestion of salt, salt water, sodium rich enemas</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>IV hypertonic infusions, e.g. sodium bicarbonate, sodium chloride</p>
</div></li>
</ul></td>
</tr>
</tbody>
</table>
<h2 id="presenting-symptoms-and-signs-1">Presenting symptoms and signs </h2>
<p>These become obvious as the hypernatraemia becomes more severe:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Thirst</p>
</div></li>
</ul>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Fever</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Sensorium change</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Seizure</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Focal neurological deficits</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Hyperventilation</p>
</div></li>
</ul>
<h2 id="management-1">Management</h2>
<p>Stop or decrease dosage of medications and infusions which are likely causes of hypernatremia.</p>
<h3 id="adults">Adults</h3>
<p><strong>Mild to moderate hypernatraemia</strong> (Na 146-159 mmol/l): oral water therapy may be sufficient.</p>
<p><strong>Severe hypernatraemia</strong> (Na &gt; 160 mmol/l): use IV 5% Dextrose with the aim to reduce Na at a rate of 0.5 mmol/hr and not more than 10 mmol/24hrs. Monitor Na every 4 hours. Note that too rapid a correction of the Na can cause cerebral oedema, convulsions and brain injury.</p>
<h3 id="children">Children</h3>
<p><strong>Mild hypernatraemia</strong> (Na 146-149 mmol/l): enourage drinking. Stop any feed fortifications (eg extra scoops of formula – not F75 or F100).</p>
<p><strong>Moderate hypernatraemia</strong> (Na 150-169 mmol/l):</p>
<p>If &quot;shocked&quot;, resuscitate with boluses 20ml/kg of 0.9% saline as required.</p>
<p>After initial resuscitation, replace the deficit plus maintenance slowly at a uniform rate <strong><a href="https://www.rch.org.au/clinicalguide/guideline_index/Hypernatraemia/#1"><span class="underline">over 48 hours</span></a>.</strong></p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Nasogastric rehydration is preferred</p>
</div>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Carefully regulate fluid intake - do not allow excessive intake in a thirsty child.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>If the serum sodium falls too rapidly (&gt; 0.5 mmol/l/hr) slow the rate of rehydration (for example, by 20%) or change to intravenous fluids.</p>
</div></li>
</ul></li>
<li><div data-custom-style="List Paragraph">
<p>If needing intravenous rehydration use <strong>0.9% sodium chloride (normal saline) and 5% Glucose</strong>. Add maintenance KCl once urine output established.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Check U&amp;Es and glucose frequently intially.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>If after 6 hours of rehydration therapy, the sodium is decreasing at a steady rate then check the U&amp;Es and glucose 4 hourly.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>If serum sodium is falling faster than 1 mmol/l/hr, stop infusate and seek senior support.</p>
</div></li>
</ul>
<p><strong>Severe hypernatraemia</strong> (Na &gt; 170 mmol/l):</p>
<p>This is a medical emergency. After initial resuscitation, aim to replace deficit and maintenance with <strong>0.9% sodium chloride (normal saline) and 5% glucose</strong> over 72 - 96 hours. Seek senior support early and monitor U&amp;Es up to hourly. Involve lab staff as soon as possible.</p>
<h3 id="calculation">Calculation</h3>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Water deficit (in litres) = TBW × ([Na/140] – 1</p>
</div></li>
</ul>
<p>This determines the amount of fluid to be infused over 48 hours.</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Change in Na = Infusate Na – Na / (total body water +1)</p>
</div></li>
</ul>
<p>This gives the change in Na per litre of infusate. If using 5% dextrose the infusate Na is 0.</p>
<p>You may use the calculator on this website to determine the rate of fluid infusion : <a href="https://www.mdcalc.com/sodium-correction-rate-hyponatremia-hypernatremia"><span data-custom-style="Hyperlink">https://www.mdcalc.com/sodium-correction-rate-hyponatremia-hypernatremia</span></a></p>
<h2 id="key-issues-for-nursing-care">Key Issues for Nursing care</h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Severe hyponatraemia and hypernatraemia can both have serious long term consequences. These can be worsened if the correction is too rapid.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Follow the fluid instructions very carefully.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Make sure repeat tests are done on time and are reviewed by a doctor promptly.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>All patients with abnormal Na levels should have strict monitoring of fluid input and output.</p>
</div></li>
</ul>
<h2 id="references">References</h2>
<p>Bartel B, Gau E. Fluid and Electrolyte Management. Critical Care Pharmacotherapeutics. Burlington, MA: Jones &amp; Bartlett Learning. 2012 Feb 8:125-50.</p>
<p>Hoorn EJ, Tuut MK, Hoorntje SJ, van Saase JL, Zietse R, Geers AB. Dutch guideline for the management of electrolyte disorders-2012 revision. Neth J Med. 2013 Apr 1;71(3):153-65.</p>
<p>Kraft MD, Btaiche IF, Sacks GS, Kudsk KA. Treatment of electrolyte disorders in adult patients in the intensive care unit. American Journal of Health-System Pharmacy. 2005 Aug 15;62(16):1663-82.</p>
<table>
<thead>
<tr class="header">
<th><strong>Written by:</strong></th>
<th><p>Orighomisan Agboghoroma</p>
<p>Mariama Sonko</p></th>
<th>Date: 07 January 2019</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Reviewed by:</strong></td>
<td>Karen Forrest</td>
<td>Date: 08 May 2019</td>
</tr>
<tr class="even">
<td><strong>Version:</strong></td>
<td><strong>Change history:</strong></td>
<td><strong>Review due date:</strong></td>
</tr>
<tr class="odd">
<td>1.0</td>
<td>New document</td>
<td>31 May 2021</td>
</tr>
<tr class="even">
<td>Review Comments (<em>if applicable)</em></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
</article>
</body>
</html>
